Florida International University

FIU Digital Commons
HWCOM Faculty Publications

Herbert Wertheim College of Medicine

11-5-2012

Image Guided Biodistribution and
Pharmacokinetic Studies of Theranostics
Hong Ding
Herbert Wertheim College of Medicine, Florida International University, hding@fiu.edu

Fang Wu
State University of New York at Buffalo

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works
3.0 License.
Follow this and additional works at: https://digitalcommons.fiu.edu/com_facpub
Part of the Medicine and Health Sciences Commons
Recommended Citation
Ding H, Wu F. Image Guided Biodistribution and Pharmacokinetic Studies of Theranostics. Theranostics 2012; 2(11):1040-1053.
doi:10.7150/thno.4652. Available from http://www.thno.org/v02p1040.htm

This work is brought to you for free and open access by the Herbert Wertheim College of Medicine at FIU Digital Commons. It has been accepted for
inclusion in HWCOM Faculty Publications by an authorized administrator of FIU Digital Commons. For more information, please contact
dcc@fiu.edu.

Theranostics 2012, 2(11)

Ivyspring

International Publisher

1040

Theranostics
2012; 2(11):1040-1053. doi: 10.7150/thno.4652

Review

Image Guided Biodistribution and Pharmacokinetic
Studies of Theranostics
Hong Ding1,2 , Fang Wu2
1.
2.

Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL33199.
Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York 14260.

 Corresponding author: Hong Ding, Department of Immunology, Florida International University, Miami, FL33199. Tel: 305-348-1490,
Fax: 305-348-1109. Email: hding@fiu.edu.
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.

Received: 2012.05.24; Accepted: 2012.06.17; Published: 2012.11.05

Abstract
Image guided technique is playing an increasingly important role in the investigation of the
biodistribution and pharmacokinetics of drugs or drug delivery systems in various diseases,
especially cancers. Besides anatomical imaging modalities such as computed tomography (CT),
magnetic resonance imaging (MRI), molecular imaging strategy including optical imaging,
positron emission tomography (PET) and single-photon emission computed tomography
(SPECT) will facilitate the localization and quantization of radioisotope or optical probe labeled nanoparticle delivery systems in the category of theranostics. The quantitative measurement of the bio-distribution and pharmacokinetics of theranostics in the fields of new
drug/probe development, diagnosis and treatment process monitoring as well as tracking the
brain-blood-barrier (BBB) breaking through by high sensitive imaging method, and the applications of the representative imaging modalities are summarized in this review.
Key words: Image, biodistribution, pharmacokinetic, theranostics, nanoparticles, antibody.

1. Introduction
The properties of biodistribution and pharmacokinetics play a major role in influencing and determining the efficacy and safety for the treatment with a
medicine. Currently, several image guided modalities
have been applied in biomedicine and even in clinic,
including magnetic resonance imaging (MRI), X-ray
computed tomography (CT), positron emission tomography (PET), single-photon emission computed
tomography (SPECT), electron microscopy, autoradiography, optical imaging and ultrasound (US), etc.
They are all noninvasive imaging modalities and
proven clinical applications, and some of them are
only extended to in-vivo research specimens as small
as mice [1, 2]. Among them, PET and optical imaging
are regarded as quantitative or semi-quantitative imaging modalities that employ radiotracers or optical

tracers to image biodistribution of the labeled drugs
or probe loaded delivery systems in the body,
meanwhile CT and MRI are normally used for anatomical imaging purposes [3, 4]. In these imaging
modalities, non-invasive technique attracted more
attention because of its properties of no breaking in
the skin and no contact with the mucosa, internal
body cavity beyond a natural or artificial body orifice.
Non-invasive in vivo molecular imaging can be obtained from PET, MR, CT and visible infrared in vivo
optical imaging systems. The discovery of the first
modern non-invasive techniques was setup at the end
of 19th century based on physical methods: electrocardiography and X-rays. From that time,
non-invasive with advantage of penetrating the body
rather than a scalpel have continuously enlarged the
http://www.thno.org
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scope of medical technology. Non-invasive techniques commonly can be used for the purpose of
theranostics by diagnostic imaging and therapy on
diseases [5-7].
The ability to quantitatively image the biodistribution of therapeutics or drug delivery systems in a
noninvasive manner can aid in the development of
new theranostic, dose optimization and treatment
monitoring. Normally, the information of biodistribution can often be obtained by dissecting the animal,
collecting plasma or tissues and being analyzed by
high-performance liquid chromatography (HPLC),
Enzyme-linked immunosorbent assay (ELISA) etc
[8-10], the key advantage of non-invasive imaging is
less time consuming and more cost effective of animals and analysis reagents [11]. There is a critical
need to establish an effective non-invasive tool to
clearly diagnose diseases along with the treatment. If
a high effective non-invasive method exists, a cancer
patient could be more potentially received effective
treatment at an earlier stage with concise targeted
drug delivery [12].
Therefore, discussions of perspectives of various
imaging guided modalities are focusing on the re-
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search applications in biodistribution and pharmacokinetics of delivery systems such as theranostics. The
concept of the revolutionary “Theranostic” was originated by Funkhouser in 2002 from one of his reviews.
Theranotics is defined as a material that combines the
modalities of therapy and diagnostic imaging at the
same time within the same dose [13]. It integrates the
two features into one “package” to overcome undesirable difference between biodistribution and therapeutic agents. The final goal of the theranostic is to
donate materials with the capacity of monitoring the
treated tissue, PK and efficacy in the long-term period. This approach will benefit nanomedicine with an
effectively style of personalized treatment. In actual
applciations, the combination of MRI, CT, PET, or
optical imaging and their combination usage may add
further impetus to the rapid and high throughput
screening of nanoparticle delivery systems based diagnosis and therapeutics (Figure 1). Some representative applications of imaging modalities in the area of
biodistribution and pharmacokinetics of nanoparticles for the aim of treatment and diagnosis are also
listed in this review.

Figure 1. Illustration of multi-functionalized nanoparticles. Examples of multifunctional nanoparticles for (i) molecular imaging for MRI or
PET/SPECT imaging; (ii) drug delivery, (iii) fluorescence detection with a fluorescent probe; (iv) X-ray images such as CT; (v) ultrasonic
assistance; (vi) specific targeting, functionalized with specific ligand molecules (e.g. antibody) and (vii) drug payload.

http://www.thno.org
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2. Magnetic resonance imaging (MRI) and
computed tomography (CT) guided biodistribution and pharmacokinetics study
Magnetic resonance imaging (MRI) is a
non-invasive medical imaging to visualize detailed
internal structures. For MR imaging, atoms in the
body are aligned under a powerful magnetic field.
Radio frequency fields change the alignment of the
magnetization of atoms. This causes the nuclei to
produce a rotating magnetic field detectable by the
scanner, which can be recorded to construct an image
of the body. Strong magnetic field gradients cause
nuclei at different locations to rotate at different
speeds, thus providing 3D spatial information. Comparing with other medical imaging techniques such as
computed tomography (CT), MRI provides good
contrast between the different soft tissues of the body,
which make it especially useful in imaging brain,
muscles, the heart, and cancers [14, 15]. Another advantage of MR imaging is that it does not need to use
ionizing radiation which has damage to cell structure
once be exposed.
X-Rays computed tomography, also called
computed tomography (CT scan) or computed axial
tomography (CAT scan), can make use of radiation to
get an internal view of the body for medical imaging
employing tomography created by computer processing. Although CT technique is regarded as birth
defects or DNA altering because of powerful X-ray
radiation exposure, it is still largely employed in hospitals, especially used for broken bones and skulls.
Not like MRI imaging which can provide subtle differences between the different kinds of soft tissues, CT
can demonstrate the difference between bone density
and soft tissue. Although MRI and X-ray are both
imaging techniques for organs of the body, the difference in application is that MRI images provide a 3D
representation of organs, which X-Rays usually cannot.
Dr. Sgouros and colleagues applied MRI based
preclinical biodistribution and localization data and
the therapeutic potential of trastuzumab monoclonal
antibody (mAb) (anti-HER2/neu) against ovarian
carcinoma. By MRI images, they found out the rapid
blood-pool uptake (5-9 hours) of mAb after intraperitoneal injection followed by tumor localization (26-32
hours). And micro-PET finding was consistent with
the data from high resolution MRI images slices for
mAb bio-distribution in main organs of tumor-beard
mice [16]. Dr. Teng et al conjugated anti-mouse OxLDL polyclonal antibody to polyethylene glycol-coated ultrasmall superparamagnetic iron oxide
(USPIO) nanoparticles, and imaged at 7.0 Tesla MRI
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on a carotid perivascular collar model in atherosclerotic disease mice. The results showed MRI signal loss
in the carotid atherosclerotic lesions after administration of targeted anti-OxLDL-USPIO at 8th hour and
24th hour, which means that anti-mouse OxLDL antibody conjugated magnetic nanoparticle can be used
as a strategy for the therapeutic evaluation of atherosclerotic plaques in vivo by MRI imaging [17].
CT became an important tool in medical imaging
to supplement X-rays and medical ultrasonography
since 1970s. It has more recently been used for preventive medicine or screening for disease. CT is regarded as a moderate- to high-radiation diagnostic
technique. The radiation dose for a particular study
depends on multiple factors: volume scanned, patient
build, number and type of scan sequences, and desired resolution and image quality. Normally, the
high resolution and image quality means the high
exposure of radiation to patients. The high ionizing
radiation in CT application can damage the DNA
double strand structure in human body. In one study,
researchers found out at a typical CT scanning,
40%-100% of the irradiated cells is damaged by one or
more double strand breaks in DNA molecule. Although there is repair process in cells for damaged and
broken DNA, the results are not satisfied [18]. That‟s
why by now, CT technique is designed to combine
with other image techniques for better application in
patients.

3. PET and SPECT image guided biodistribution and pharmacokinetics study of
theranostics
3.1 Radiolabeling of antibody therapeutics and
principle of PET imaging
PET imaging is another kind of non-invasive
option for diagnosis. Since biodistribution of antibody-based therapeutics is a key consideration that
can be modulated to impact the ensuing in vivo
pharmacological effect. After being labeled with radionuclide of sufficient long half-life, antibody therapeutics can be monitored using PET (positron emission tomography) imaging with respect to pharmacokinetics and its biodistribution. Normally, it is assumed that the labeling method does not perturb the
property of the molecules with respect to metabolism,
specific binding or non-specific interactions. The labeling isotopes include positron emitters such as 11C,
15O, 18F, 68Ga, 64Cu, or 76Br with half-lives of 20
minutes, 2 minutes, 2 hours, 68 minutes, 13 hours, and
16 hours respectively. Long-lived positron emitters
such as 89Zr and 124I with half-lives of several days,
3.2 days for 89Zr and 4.2 days for 124I, are also available
http://www.thno.org

Theranostics 2012, 2(11)
[19]. Among them, Copper-64 (64Cu) is a promising
PET radionuclide, particularly for antibody-targeted
imaging [20]. The reported methods for modification
include addition of labeled groups or radiolabel chelating groups. Compared with radio-halogenation,
radiometal ion complexation reactions have simpler
chemistry and allow tracer production kits. For example, chelator 1, 4, 7, 10-tetraazacyclododecane-1, 4,
7, 10-tetraacetic acid (DOTA) is commonly used in
radiolabeling copper radioisotope with antibody [21].
„MicroPET‟ is a small-animal positron emission
tomography which uses pharmacologically or biochemically active compounds labeled with short-lived
or long-lived positron-emitting radionuclides to
monitor their biodistribution, physiological processes
and biochemical pathways etc [22]. These radionuclides are incorporated into molecules during the radiosynthesis step, generating the radiotracer. PET
scans are acquired following the injection of the radiotracer. The radiotracer accumulates in the tissues,
and its radionuclide decays by emission of a positron
(anti-electron). After travelling at most a few millimeters, a positron will collide with an electron, simultaneously releasing two gamma rays (photons) with
energy of 511 keV into opposite directions. These two
photons are detected by the PET camera and by collecting a statistically significant number of radioactive
events, mathematical algorithms reconstruct a
three-dimensional image that shows the distribution
of the positron-emitting molecules in the tissues [19].
Single-photon emission computed tomography
(SPECT) is also one kind of nuclear medicine tomographic imaging technique using gamma
rays which can provide 3D information as PET as
well. Normally, a marker radioisotope could be attached to an nanoparticles or antibody. After being
administered in vivo, the gamma-emission of the
isotope from the radiolabeled materials allows the
drug to be seen by a gamma-camera. SPECT can generate a true 3D image, which permit accurate localization of organs. Therefore, it can be used to provide
information about localized function in internal organs, such as functional cardiac or brain imaging [11].

3.2 PET images guided biodistribution and
pharmacokinetic study of theranostics
Targeted therapeutic and diagnostic nanocarriers functionalized with antibodies, peptides or other
targeting ligands that recognize over-expressed receptors or antigens on tumor cells have potential in
the diagnosis and therapy of cancer. Biodistribution
study of therapeutic antibodies by PET methodology
could quantitatively measured by radiotracer in organs/tissues. Biodistribution and pharmacokinetics
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could also be recorded by blood sampling at predetermined time points, preferably associated with radiometabolite evaluation with respect to time [23].
PET images were used from heart to determine blood
concentrations. Briefly, nude mice bearing human
colon tumors (LS-174T) were injected intravenously
with a chimeric 124I anti-CEA mAb (cT84.66) and imaged serially 1 hour to 7 days postinjection. The results showed that PET blood curves agreed well with
direct measurements within 12% at all time points.
The 4.2-day half-life of 124I favors its use for PET study
of monoclonal antibodies (mAbs). Therefore, quantitative biodistribution measurements could be
achieved from tumor-bearing mice by using 124I anti-CEA mAbs with standard microPET acquisition
and processing techniques. Although from the ROI of
heart on the PET images, the blood concentrations can
be calculated, most of the case, the pharmacokinetic
study was done by withdrawing blood sample and
analyzing them with radioassay or ELISA [24].
The distribution of monoclonal antibodies is determined by the rate of extravasation in tissue, the rate
of distribution within tissue, binding affinity in tissue
and the rates of elimination from tissue, route of injection, species etc. Although PET imaging has been
applied in the study of Integrin αVβ3 expression or
peptide antagonist [25-27], the mAbs are large molecules with MW of about 150 kDa, it seems to be very
slow for them to diffuse across vascular endothelial
cells. The movement of antibody into tissue by convective transport is thought to be the primary mechanism for the distribution in tissue [28]. The transport
is mainly determined by the movement rate of fluid
from blood to tissue and by the sieving effect of
paracellular pores in the vascular endothelium. Normally, the biodistribution of drugs requires sacrificing
a number of rodents and quantitating the tissue concentration by HPLC, ELISA or by counting the radioactivity emitting from the tissue. MicroPET imaging
provides a non-invasive way of quantitation of the
concentration of mAbs in tissues, especially useful for
monitoring the kinetics in target organ such as tumor.
For instance, a chimeric anti-CD105 monoclonal
antibody,
TRC105,
was
conjugated
to
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid (DOTA) and labeled with (64)Cu. Serial PET
imaging revealed that the 4T1 tumor uptake of the
tracer was 8.0 ± 0.5, 10.4 ± 2.8, and 9.7 ± 1.8%ID/g
(percentage of injected dose per gram tissue) at 4, 24,
and 48 h post-injection, respectively, higher than most
organs at late time points which provided excellent
tumor contrast. Biodistribution data as measured by
gamma counting were consistent with the PET findings [11]. Non-invasive PET imaging of vascular enhttp://www.thno.org
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dothelial growth factor (VEGF) expression using radiolabeled bevacizumab has been investigated in
ovarian cancer models [29]. Small-animal PET and
microCT images were used to calculate tumor uptake
and compared with ex vivo biodistribution at 168 h
after injection. The tumor accumulation of 89Zr labeled
bevacizumab was calculated to be 7.38 %ID/g using
small-animal PET imaging, which is equivalent to ex
vivo biodistribution studies. Liver and spleen were
the other organs that uptake tracer bevacizumab. This
project demonstrated the quantization of radio-labeled bevacizumab in tumor using non-invasive
imaging is convenient, which was also validated by ex
vivo biodistribution studies. Since VEGF is a major
angiogenic factor responsible for the development of
tumor vasculature, the expression level of VEGF
could be regarded as a factor indicating disease progress. PET imaging were performed in mice bearing
human colorectal cancer (HT29) xenografts to investigate the in vivo biodistribution of VEGF after injection of 64Cu-DOTA-bevacizumab. The accumulation
of 64Cu-DOTA -bevacizumab in the tumor was 22.7
%ID/g, 24 %ID/g, 19.0 %ID/g at 24, 48 and 72 h, respectively, which was significantly correlated with
VEGF expression as measured by western blot (q =
0.81, P = 0.004) [30].
Currently, the PK and biodistribution were also
conducted not only for antibodies, but also for antibody or peptide functionalized theranostics. For example, Dr. Cai W etc. employed PET imaging using
(66)Ga as the radiolabel to quantitatively evaluate the
pharmacokinetics and tumor targeting efficacy of
nano-graphene. Nano-graphene oxide (GO) sheets
with covalently linked, amino group-terminated
six-arm branched polyethylene glycol (PEG; 10 kDa)
chains
were
conjugated
to
NOTA
(1,4,7-triazacyclononane-1,4,7-triacetic
acid,
for
(66)Ga-labeling) and TRC105 (an antibody that binds
to CD105). TRC105-conjugated GO was specific for
CD105 in cell culture. (66)Ga-NOTA-GO-TRC105 and
(66)Ga-NOTA-GO exhibited excellent stability in
complete mouse serum. In 4T1 tumor-bearing mice,
these GO conjugates were primarily cleared through
the hepatobiliary pathway. (66)Ga-NOTA-GOTRC105 accumulated quickly in the 4T1 tumors and
tumor uptake remained stable over time (3.8 ± 0.4, 4.5
± 0.4, 5.8 ± 0.3, and 4.5 ± 0.4 %ID/g at 0.5, 3, 7, and 24 h
post-injection respectively; n = 4). PET imaging successful demonstrated the in vivo tumor targeting
property with GO, showing them to be suitable nanoplatforms for future biomedical research such as
cancer theranostics [31].
Andresen TL et al covalently attached octreotate
(TATE) to the distal end of DSPE-PEG(2000) on
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PEGylated liposomes with an encapsulated positron
emitter (64)Cu that can be utilized for PET imaging.
TATE are somatostatin peptide analogs, can target
Somatostatin
receptors
(SSTRs)
that
are
over-expressed in neuroendocrine tumors (NETs).
They used PET imaging to investigate the biodistribution and pharmacokinetics of the (64)Cu-loaded
PEGylated liposomes with and without TATE. They
found that the presence of TATE on the liposomes
resulted in a significantly faster initial blood clearance
in comparison to control-liposomes without TATE.
PEGylated liposomes with or without TATE accumulated at significantly higher quantities in NETs
(5.1±0.3 and 5.8±0.2 %ID/g, respectively) than the free
peptide (64)Cu-DOTA-TATE (1.4±0.3 %ID/g) 24h
post-injection. Importantly, (64)Cu-loaded PEGylated
liposomes with TATE showed significantly higher
tumor-to-muscle (T/M) ratio (12.7±1.0) than the control-liposomes without TATE (8.9±0.9) and the
(64)Cu-DOTA-TATE free peptide (7.2±0.3). The higher T/M ratio of the PEGylated liposomes with TATE
suggests some advantage of active targeting of NETs,
although no absolute benefit in tumor accumulation
over the non-targeted liposomes was observed. The
results showed that (64)Cu-loaded PEGylated liposomes with TATE conjugated to the surface could be
promising new imaging agents for visualizing tumor
tissue and especially NETs [32].

3.3. SPECT images guided biodistribution and
pharmacokinetics study of theranostics
Single-photon emission computed tomography
(SPECT) is a nuclear medicine tomographic imaging
technique using gamma rays. Normally, a marker
radioisotope could be attached to nanoparticles or
antibody. After being administered in vivo, the
gamma-emission of the isotope from the radiolabeled
nanoparticles or antibody allows the drug to be seen
by a gamma-camera.
Since the source of SPECT images are gamma ray
emissions, the radioisotope decays and emits gamma
rays, which can be detected by a gamma camera to
obtain 3D images, which permit accurate localization
of organs [33]. This information is typically presented
as cross-sectional slices through the patient, but can be
freely reformatted or manipulated as required.
Therefore, it can be used to provide information about
localized function in internal organs, such as functional cardiac or brain imaging. For example, 3D acquisition SPECT of the liver was performed to investigate the correlation between tumor accumulation of
In-111-bevacizumab and VEGF-A expression in patients with colorectal liver metastases [34].
Although heart has been used as an organ in PET
http://www.thno.org
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imaging to estimate blood concentration, for pharmacokinetic study using SPECT imaging, the commonly used method is to collect blood samples from
patients or animals at timed intervals after injection of
the radioisotope-labeled mAb [23]. The major advantages of radionuclide-based molecular imaging
techniques (SPECT and PET) over other modalities
(e.g. optical and MRI) are that they are very sensitive
(down to the picomolar level), quantitative, and there
is no tissue penetration limit. However, one disadvantage is that the resolution (typically >1 mm) of
either SPECT or PET is not as high as the other imaging modalities such as MRI. In most cases, the purpose of labeling the nanoparticle with a radionuclide
was for the non-invasive evaluation of its biodistribution, pharmacokinetic properties, and/or tumor-targeting efficacy with SPECT or PET [35,
36]. Radiolabeling of nanoparticles was also applied
for PK and biodistribution studies for the purpose of
theranostics. Dr. Helbok et al radiolabeled
DTPA-derivatized lipid-based nanoparticles including including (111)In and (99m)Tc for SPECT and PET
images with therapy in vitro and in vivo. Their study
showed that PEGylated DTPA-nanoparticles were
suitable for targeting applications. Biodistribution in
Lewis rats revealed no significant differences between
nanoparticles in terms of DTPA loading and particle
composition; however, different uptake patterns were
found between the radionuclides used [37]. Dr. DeNardo et al applied 111In-labeled, chimeric L6 (ChL6)
monoclonal antibody linked iron oxide (IO) nanoparticles for studies on pharmacokinetics, tumor uptake,
and therapeutic efficacy in athymic mice bearing human breast cancer tumors. The 111In-labeled ChL6
was conjugated with carboxylated polyethylene glycol (PEG) on dextran-coated iron oxide nanoparticles
with one to two ChL6 antibodies per nanoparticle (Fig
2). Inductively heating the nanoparticle by externally
applied alternating magnetic field caused tumor necrosis after 24 h of therapy. After nanoparticle injection, SPECT imaging was carried out to quantify the
nanoparticle uptake in the tumor, which was about 14
percentage injected dose per gram (%ID/g) at 48 h
post-injection. A delay in tumor growth occurred after
the alternating magnetic field treatment, which was
statistically significant when compared with the untreated group [38, 39]. Dr. Misri and colleagues also
applied SPECT imaging for mesothelin expressing in
tumors by evaluation of 111In labeled antibodies.
Their findings indicated that the antimesothelin antibody mAbMB may be developed into a diagnostic
agent for imaging mesothelin-expressing cancers [40].
Dr. Wu et al also successfully applied gamma scintigraphy by pulsincap capsule in the gastrointestinal
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tract of dogs by to find out the desintegration and
transit behavior of Tetramethylpyrazine phosphate.
Their SPECT images confirmed the time controlled
capsule releasing in the gastrointestinal delivery in
dog at the expected time schedule [41].

Figure 2. Simple radioimmuno-nanoparticles diagram of a
BNF-type particle coated with PEG to link 111In-ChL6. The particle core has ferromagnetic property. Adapted from [39].

4. Combination of PET and SPECT with
CT, MR or NIRF images guided biodistribution and pharmacokinetic studies of
theranostics
Imaging modalities such as CT and PET have
been applied sequentially in the diagnosis and staging
of disease and in monitoring the effects of therapy for
several years. Although PET offers high sensitivity in
terms of molecular concentrations and it is possible to
measure picomolar amounts of a PET radiopharmaceutical in a tissue. With a three dimentional images
obtained by PET, establishing a ROI (region of interest) and set the location of the organs or tissues in the
images is of critical importance. Since accurate anatomic localization of functional abnormalities seen on
PET scans is well known to be challenging because of
the lack of detailed, high-resolution anatomy, the fusion of PET with CT in one camera unit (PET/CT) or
fusion of PET image with MR images provides a
merged image where not only the physiological status
but also the anatomical details may be seen on the
same image, which opens new ways of diagnostics
and quantitation [42-46]. Indeed, in many cases anatomic imaging is used exclusively, although functional imaging with PET is fulfilling an increasingly

http://www.thno.org
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important role in the staging and therapy monitoring
processes, particularly when the CT scan is equivocal.
This situation changed dramatically with the recent
introduction of the combined PET/CT scanner, an
approach that solves the fusion problem through
hardware rather than software. This device provides a
medical imaging department with the capability to
acquire accurately aligned anatomic and functional
images for a patient from a single scanning session
[47]. In another word, anatomical/functional imaging
techniques help to identify the exact location of the
signals. Since the patient remains positioned on the
same bed for both imaging modalities, temporal and
spatial differences between the two sets of images are
minimized.
Schneider DW et al used whole-body
small-animal PET to compare the bisodistribution and
tumor localization of 86Y or 111In-labeled antibody
formats, derived from a single antimindin/RG-1 mAb
in a prostate tumor model. The images were colocalized with simultaneous micro-CT imaging. The antibody accumulation in the tumor correlated with molecular size. The larger antibody formats (IgG and
miniantibody) gave higher tumor uptake levels than
did the smaller formats (diabody and scFv). These
larger formats may be more suitable for radioimmunotherapy applications. The smaller formats were
rapidly cleared from circulation, and the diabody,
which accumulated in the tumor, may be more suitable for radiodiagnostic applications. The combination
of PET with CT provides easier localization of tissues
[34, 48].
PET is sensitive in the process of detecting and
quantifying a low abundance molecular target in cells
while MRI is capable of providing exquisite anatomy
for organs. Thus, an integrated PET/MRI system will
permit the simultaneous acquisition of several parameters in highly accurate spatial and temporal registration. Quantitative values from PET of a large
number of biological parameters are complemented
by the high-resolution information provided by MRI
(in the micromolar range) to yield complementary
information. An MRI-based method has the potential
to improve PET image quality, increasing its reliability, reproducibility, and quantitative accuracy [49].
PET data and MRI data have been combined for
monitoring the drug anticancer effect [50], the response of patients to antibody treatment [51] as well
as for detection of lymph node metastases [52], which
is very important for the improvement of tumor detection and for the guide of mAb-based therapy.
Overall, accurate quantization of PET tracer uptake levels in tumors is important for staging and
monitoring response to treatment. The combination
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with anatomical information obtained from CT will
improve quantization of tumor values in terms of bias
and variance [53]. Using appropriate software to fuse
PET and CT image together and accurately quantify
the tumor uptake level of tracer is of critical value.
There is PET/CT scanner available for clinical study
for the [54-56]. However, the integrated equipment
which combines microPET and contrast-enhanced
microCT for small animal study is still at the starting
beginning stage [57, 58].
PET and NIRF imaging was also combined to
study
the
ex
vivo
biodistribution
64Cu-DOTA-NuB2-Alexa Fluor 750 in CD20 positive
Raji lymphoma-bearing mice. Raji tumor showed significantly higher uptake of DOTA-NuB2-Alexa Fluor
750 than that of DOTA-Alexa Fluor 750 (p<0.05). Significant correlation was obtained between the organ-to-muscle ratios measured by the radioactivity
and fluorescence intensity [59]. In Xie's work, iron
oxide nanoparticles with triple functional of
PET/NIRF/MRI were applied for the in vivo biodistribution study. To assess the biophysical characteristics of this novel nanosystem, the HSA coated IONPs
(HSA-IONPs) were dually labeled with 64Cu-DOTA
and Cy5.5, and tested in a subcutaneous U87MG
xenograft mouse model. In vivo PET/near-infrared
fluorescence (NIRF)/MRI tri-modality imaging,
and ex vivo analyses and histological examinations
were carefully conducted to investigate the in vivo behavior of the nanostructures. This nanosystem is
well-suited for dual encapsulation of IONPs and drug
molecules, with the compact HSA coating, the
HSA-IONPs manifested a prolonged circulation
half-life; more impressively, they showed massive
accumulation in lesions, high extravasation rate, and
low uptake of the particles by macrophages at the
tumor area [60].
SPECT has been combined with MRI to investigate the pharmacokinetics and biodistribution. For
example, 99mTc-labeled superparamagnetic iron oxide nanoparticles were employed for multimodality
SPECT/MRI of sentinel lymph nodes. In Dr. Madru's
work, Nanoparticles with a solid iron oxide core and a
polyethylene glycol coating were labeled with
(99m)Tc. Wistar rats was injected subcutaneously and
sacrificed 4 h after injection. Animals were imaged
with SPECT/MRI and the microdistribution within
the lymph nodes was studied with digital autoradiography. The result showed that the accumulation of
(99m)Tc-labeled superparamagnetic iron oxide nanoparticles (as the percentage injected dose/g
[%ID/g]) in the lymph nodes was 100 %ID/g,
whereas in the liver and spleen it was less than 2
%ID/g. Digital autoradiography images revealed a
http://www.thno.org
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nonhomogeneous distribution of (99m)Tc- labeled
superparamagnetic iron oxide nanoparticles within
the lymph nodes; nanoparticles were found in the
cortical, subcapsular, and medullary sinuses [61].

5. The optical imaging guided biodistribution and pharmacokinetics study of
theranostics
Optical imaging is a photonic technique which
applied in the area of imaging, describing the behavior of visible, ultraviolet, and infrared light used in
imaging [62, 63]. These optical techniques, such as
bioluminescence and fluorescence, are emerging as
powerful new modalities for molecular imaging in
disease diagnosis and therapy. Optical imaging offers
higher sensitivity and temporal resolution than PET at
the same spatial resolution in small animals, but unlike PET is limited to a few centimeters of tissue depth
[35]. The bioluminescence and fluorescence can be
obtained from dyes, specific metal materials, and biological resources etc and already used in diagnosis
and therapy in research and clinic [64-66]. With the
help of combing of innovative molecular biology and
chemistry, scientists have developed optical methods
for imaging a variety of cellular and molecular processes in vivo, including the receptor-ligand interaction, tumor targeting, bio-distribution of proteins such
as antibody, etc. Whereas optical imaging has been
used primarily for research in small-animal models, in
some specific area optical imaging may have the possibility to translate into clinical medicine. The advantages of optical imaging for assessing antibody
pharmacokinetics in vivo are the conjugation chemistry, cost, and high-speed throughput. The fluorophore
conjugation chemistry is often carried out with a
commercially available kit and can be performed in
most laboratories without special license, equipment,
hazardous precautions, or specific training. The detection systems are generally 30 to 50% as expensive
as those for small-animal SPECT or PET. Planar fluorescence images are generated within seconds or
minutes, typically with a photograph overlay. Optical
imaging experiments also can accommodate four to
five animals per scan, allowing an efficient researcher
to perform 100+ animal images per hour, whereas
PET and SPECT imaging is often limited to one to two
animals per 10 to 30 min scan. Such throughput and
cost combined with expected improvements in quantification from advances in instrumentation provide
an exciting outlook for this preclinical fluorescence
imaging approach [67].
A key challenge for pharmacists and clinic doctors is defining the disposition of drugs such as mon-
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oclonal antibody and pharmacokinetic property in
whole animals or patients. Ongoing discoveries of
these potential target molecules in disease also drive
pharmaceutical and biotechnology companies to find
leading agents that selectively regulate these molecular pathways in vitro and in vivo. Among all the existing techniques, optical imaging including bioluminescence and fluorescence, are emerging as key techniques to meet these challenges and advance molecular imaging in preclinical research and patient care.
Bioluminescence is the process of light emission in
living organisms, it is a chemical process wherein
light is emitted during the interaction of a protein
produced in engineered cells and an administered
substrate, for example firefly luciferase and luciferin
[68]. Bioluminescence imaging
is a technology
developed over the past decade that allows for the
noninvasive study of ongo-ing biological processes in
small laboratory animals. Bioluminescence imaging
utilizes native light emission from one of several organisms which contain bioluminescence. Fluorescence is the emission of light by a substance that has
absorbed light or other electromagnetic radiation with
a different wavelength. It is a form of luminescence.
Fluorescence imaging uses probes that emit light
(fluorescence) after the excitation at a fluorophore-specific wavelength. In most cases, emitted
light has a longer wavelength, and therefore lower
energy, than the exciting source, known as the Stokes
shift [69]. Dr. Wu and colleagues applied NIR dye
labeled Bevacizumab antibody to find out the pharmacokinetics, lymph Node Uptake and mechanistic
PK behavior model after i.v. and s.c. administration in
mice [70, 71]; they also found an interesting phenomena that after s.c. administration in mice, the
lymph node uptake of proteins in mice had a molecular weight dependence by the way of fluorescence
imaging [72]. This finding may provide quite useful
aim for the future protein biodistribution and pharmacokinetic studies.
The most important application of optical imaging in the biological field is early cancer detection or
diagnosis in preclinic and clinic studies, they provided a very useful alternative modality for tumor
imaging [73]. Dr. Hülper P and his colleagues published their finding of tumor localization of nti-TGF-β
antibody and its effects on gliomas. The orthotopic
gliomas beared mice was subcutaneous injected with
AF680-labeled 1D11, a pan-neutralizing TGF-β antibody, and used for the bio-distribution study via in
vivo imaging and fluorescence microscopy. With the
combination of results from direct tumor size measurement, H&E staining and immune-histochemistry,
it demonstrate that TGF-β plays different roles in
http://www.thno.org
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combating the tumor depending on subcutaneous
versus orthotopic implantation site [74]. Besides the
monoimaging principle, combining two or more different imaging modalities in the same agent can be of
considerable value in molecular imaging. By binding
a biotinylated anti-Her2 Herceptin antibody to provide tumor targeting, a biotinylated DOTA chelator
labeled with 111In and a biotinylated Cy5.5 fluorophore to a streptavidin nanoparticle, the imaging results show high tumor accumulation and strong tumor-to-normal tissue contrast by both fluorescence
and nuclear imaging. The subsequent biodistribution
study confirmed the specific tumor accumulation of
radioactivity at 40 h was 21 ID%/g and therefore
much higher than all other tissues including liver,
heart, kidney, spleen, and muscle that accumulated
8.7, 2.5, 6.9, 7.2, and 1.9 ID%/g, respectively [75]. In
Cohen‟s work, IRDye800CW was coupled with monoclonal antibodies of cetuximab and bevacizumab
with 89Zr multi-labeling for optical imaging of tumor
targets. The biodistribution studies showed that blood
clearance was enhanced and live uptake was increased at 24 to 72 hours post injection when 2 or
more eq of dye had been coupled to mAbs. This study
realized that after labeling with IRDye800CW, optical
imaging can be used for accurate quantification of the
biodistribution of mAbs (Figure 2) [76].

Figure 3. Optical imaging with 89Zr-bevacizumab-IRDye800CW
in a tumor-bearing mouse. Adapted from [76].
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In the area of cancer diagnosis, organic dye and
semiconductor nanocrystals (so called quantum dots
(QDs) or quantum rods (QRs) attract attentions because of its unique optical properties to be fluorescent
probes or luminescent nanoprobes for biological applications, ranging from immunoassays to live cell
and tissue imaging, especially in cancer detection
[77-82]. Such nanomaterials have their advantages
over traditional fluorescent probes such as organic
dyes and fluorescent proteins [79, 83]. For example,
they have robust photochemical stability, high quantum yield, and excellent resistance to chemical and
photochemical degradation, as well as size-tunable
photoluminescence that ranges from visible to near-IR
with sharp spectral bands [84]. Also, QDs with different emission colors can be simultaneously excited
with a single light source, with minimal spectral
overlap, providing significant advantages for multiplexed detection of molecular targets [85, 86]. Thus,
with conjugation with antibody and drug on the same
QDs, this kind of theranostic reagent can be used as
new type of probes for optical bioimaging and treatment on cancer.
Although there are significant advantages of
semi-conductor nanocrystal QDs in the application of
optical imaging for cancer detection, the potential
toxicity cannot be ignored due to the existing of
Cadmium element component inside the particles. In
order to alleviate possible toxicity and increase the
stability of QDs in biological field, Ding et al successfully employed carboxyl functional Pluronics
F127 (F127COOH) into the antibody conjugated QDs
for pancreatic cancer detection and obtained satisfied
results. They successfully applied anti-mesothelin
antibody in vivo for pancreatic cancer detection [87].
The in vitro and in vivo toxicity study showed the low
damage to cells and tissues in small animals. Another
alternative on optical imaging is using biodegradable
polymer encapsulated NIR dye for cancer detection
[88]. With proper fluorescent dye or drug encapsulation, this kind of biodegradable copolymer can be
conjugated with target ligands or specific antibody for
all purpose of tumor targeting. Because of the concerning about the possible toxicity, researchers also
generated a “pure” bioconjugated luminescent silicon
quantum dots for cancer detection [89, 90]. This kind
of luminescent probe can even used for sentinel
lymph node mapping since it is one of the most important site that the metastatic happened [91]. Although the above nanomaterials have their advantages
over traditional fluorescent dye probes, batch to batch
reproducibility and quantization of the labeled drug
still need further investigation. Whether the biodistribution of the labeled therapeutic antibodies is sighttp://www.thno.org
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nificantly affected by the nanomaterials remains a
question to be addressed.
Over the past years, different kinds of optical
imaging techniques have been developed for biomedical applications, including various microscopy
methods for in vitro and ex vivo applications as well
as several methods for in vivo applications such as
bioluminescence imaging, fluorescence imaging, ultrasound, dark field, diffused optical tomography,
and optical coherence tomography, etc. Not only with
help from expertise from studies on materials, various
techniques can be used in combination, either simultaneously or sequentially, to provide complementary
information from the same cells, tissues, organs, or
animals [92-96]. Dr. Chen‟s lab applied fluorescent
Maestro imaging system by real-time video imaging
of protease expression in vivo, they found out that
PEGylation of a molecular beacon with a specific size
PEG can significantly alter the activation properties of
the probe targeting matrix metalloproteinases
(MMPs). And MMPs are a family of zinc-dependent
endopeptidases and represent the most well-known
proteases associated with tumorigenesis [97].
Among them, both fluorescence and bioluminescence imaging techniques have been found wide
applications for in vivo tumor optical imaging in
mouse models and afford convenient, frequent visualization and measurement of tumor biomarkers in a
real time, sensitive, and noninvasive way. It also can
allow for longitudinal detection of disease progression and therapeutic response in the same animals so
as to minimize the subject-to-subject variability and
reduce the animal number required by a traditional
method. Importantly, such in vivo studies are very
valuable for bridging the gap between in vitro and in
vivo studies and facilitating preclinical and further
translational studies [98].

6. Images guided engineered nanoparticles and antibodies cross blood-brain
barrier (BBB)
The blood-brain barrier (BBB) is a special tight
capillaries membrane in CNS that formed from a continuous layer of endothelial cells bound together with
tight junctions that allow very little transcellular or
pericellular transport of molecules in blood fluid [99].
The BBB is an obstacle for clinicians and complicates
the treatment of diseases of the central nervous system (CNS). In order to develop BBB associated
theranostic techniques, neuroimaging techniques
have become increasingly important in assessing the
biologic and physiologic properties of brain tumors
and neurologic lesions (11). Although there are many
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successful imaging platforms including X-ray tomography (CT), optical imaging, positron emission
tomography (PET), single-photon-emission computed
tomography (SPECT), ultrasound (US), and magnetic
resonance imaging (MRI), etc. MRI and combining
with US seems the most successful applications in the
clinic.
Nanoparticles of course can be employed as effective tool for theranostic purpose. One biocompatible stealth nanoparticles were designed by using microemulsion methodology to optimize BBB circumvention and encapsulate drugs for brain delivery. In
vitro and in vivo data showed that the formulation
has no effect on BBB barrier integrity and membrane
permeability, or alteration of expression of the BBB
tight-junction proteins, occludin, and claudin-1 while
crossing BBB [100]. This kind of nanoparticles can be
applied in theranostic through BBB. Nanoparticles
encapsulation or conjugation of transporter substrates
have already been used for enhance the access of
drugs to the brain. In last decade, nano-sized carrier
comprised by polymer, emulsion, liposome, nanocrystals, micelles and etc, are already make great
progress in pharmaceutical field for drug targeting
and imaging. Dr. Ding and his colleagues applied
inorganic gold nanords for siRNA delivery into brain
has been succeeded in vitro and in vivo based on their
contrast property in cancer detection [64, 101-103].
They also applied fluorescent nanocrystal as
theranostic carrier for CNS drug delivery system
[104]. Dr. Koffie et al prepared biodegradable
nanocarrier
systems
made
up
of
poly(n-butylcyanoacrylate) dextran polymers coated
with polysorbate 80 (PBCA nanoparticles) to deliver
BBB-impermeable molecular imaging probes into the
brain for targeted molecular neuroimaging. They
demonstrated that PBCA nanoparticles using as in
vivo targeting of BBB-impermeable contrast agents
can deliver BBB-impermeable targeted fluorophores
of a wide range of sizes: from 0.5k-Da targeted polar
molecules to 150k-Da tagged immune- globulins into
the brain of living mice model of Alzheimer's disease.
PBCA nanoparticles do not induce nonspecific BBB
disruption, but collaborate with plasma apolipoprotein E to facilitate BBB crossing [105]. Dr. Qiao et al
conjugated lactoferrin (Lf) with poly(ethylene glycol)
(PEG)-coated Fe3O4 nanoparticle to cross BBB by receptor-mediated transcytosis via the Lf receptor present on cerebral endothelial cells. The MRI images
confirmed that in vivo experiments, Fe3O4-Lf probe
exhibited an enhanced effective measure for delivering the nanoparticles across the BBB [106, 107].
It is well-known that few of those antibodies can
penetrate the shield of tightly packed cells known as
http://www.thno.org

Theranostics 2012, 2(11)
BBB. Normally, antibody concentrations in the brain
are typically about a thousand times lower than in the
blood. In the recent finding, Dr. Watts and his collaborators report the design of an antibody that surmounts this obstacle. This antibody had the function
of targeting two proteins. One is called β-secretase 1,
which is a popular target for drugs to treat Alzheimer's disease; the second protein targeted by the antibody is the transferrin receptor, which activates a
molecular channel that normally imports iron into the
brain. By clinging to this receptor, the antibody is
transported into the brain, where it can act against
β-secretase 1. The double-duty antibody performed
well in mouse models of Alzheimer's disease: a day
after receiving a single injection of the antibody, concentrations of amyloid-β in the brain plummeted by
47% [108, 109].
Lee et al applied peptidomimetic monoclonal
antibodies that target peptide transcytosis systems for
the BBB in vivo. Murine monoclonal antibodies to the
rat transferrin receptor, such as the OX26 monoclonal
antibody, are targeted through the BBB on the transferrin receptor in the rat. The capillary depletion
technique demonstrated transcytosis of the RI7-217
rat monoclonal antibodies antibody can through the
mouse BBB in vivo. The studies indicate rat monoclonal antibodies to the mouse transferrin receptor
may be used for brain drug-targeting studies [110].
Dr. Boado and his colleagues used engineered murine
monoclonal antibody to the human insulin receptor
(HIR) as a brain drug delivery system for transport
across the human BBB (Figure 4). The HIRMAb was
humanized by complementarity determining region
(CDR) grafting on the framework regions (FR) of the
human B43 IgG heavy chain and the human REI
kappa light chain. The humanized HIRMAb avidly
bound to the HIR of isolated human brain capillaries,
which are used as an in vitro model system of the
human BBB. The humanized HIRMAb was radiolabeled with 125-iodine, and injected intravenously
into an adult, anesthetized Rhesus monkey. Brain
scanning showed the humanized HIRMAb was rapidly transported into all parts of the primate brain
after intravenous administration. The humanized
HIRMAb may be used as a brain drug and gene delivery system for the targeting of large molecule
therapeutics across the BBB in humans [111].
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7. Conclusions and Perspectives
Molecular imaging takes advantage of the traditional diagnostic imaging techniques and introduces
molecular imaging probes to measure the expression
of indicative molecular markers at different stages of
diseases. It has been widely reported the importance
and advantages of various imaging modelities in the
drug development. We summarized the distribution
and pharmacokinetics studies using MR imaging, CT,
PET imaging, SPECT imaging, optical imaging as well
as SPECT etc. Among those imaging modalities, PET,
SPECT and MRI imaging has been used in clinical
study, while optical imaging is still on the way of getting through; almost all of the studies using optical
imaging are in the preclinical status. Non-invasive
detection of various molecular markers of diseases
can allow for much earlier diagnosis, earlier treatment, and better prognosis that will eventually lead to
personalized medicine. For using molecular imaging
to investigate the biodistribution and PK properties of
theranostics, the following aspects still need further
investigation:

Figure 4. Film autoradiography of Rhesus monkey brain removed
2 h after an intravenous administration of [125I]-humanized
HIRMAb. Coronal sections through the forebrain (top panel),
midbrain (middle panel), and hindbrain/cerebellum (bottom panel)
are shown. Adapted from [111].

http://www.thno.org
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 Major advantages of radionuclide-based molecular imaging techniques (SPECT and PET) over
other modalities (optical and MRI) are high sensitivity (picomolar level), quantitation, and
non-tissue penetration limitation. However, one
disadvantage is that the resolution of either
SPECT or PET is not as high as MRI. In most
cases, the modalities such as PET or SPECT can
be applied for studies of biodistribution, PK
study properties, and/or tumor-targeting efficacy in non-invasive image ways.
 Comparing with other medical imaging techniques such as CT, MRI provides good contrast
between the different soft tissues of the body,
which make it especially useful in imaging brain,
muscles, the heart, and cancers. CT is preferable
in the application of bones imaging while MRI is
good for tissue imaging.
 For both PET imaging and optical imaging, the
image only showed the signals from the radioisotope probe or fluorophore probe, while the
probe may still attach to the metabolite of drug
even after the degradation of the drug. Therefore,
the imaging method is not able to distinguish the
metabolite or parent drug. Using sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) or size exclusion HPLC for confirming the stability of the labeled antibody
therapeutics may be a good way of providing
more information of metabolism. For labeled
antibody, due to its therapeutic effect and detective property, the labeled antibody can also be
considered as theranostics if it is used in the field
of treatment and diagnosis.
 After obtaining biodistribution data using molecular imaging in preclinical study, establishing
physiologically based pharmacokinetic model
(PBPK) and allometric scaling for translation of
animal data to human clinical pharmacology is
very important. Further research effort is needed
on establishing PBPK model using imaging data.
 For the later clinical application, the absorption,
distribution, metabolism/degradation and excretion of theranostics need to be extensively
studied. Various imaging modalities mentioned
in this review are useful quantitative tools for
investigating the above biopharmaceutical
properties of theranostis.
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sorbent assay; FR, framework regions; HIR, human
insulin receptor; HPLC, high-performance liquid
chromatography; Lf, lactoferrin; mAbs, monoclonal
antibodies; MRI, magnetic resonance imaging; NETs,
neuroendocrine tumors; NIRF, near-infrared fluorescence; PBCA, poly(n-butylcyano- acrylate) dextran
polymers coated with polysorbate 80; PBPK, physiologically based pharmacokinetic model; PET, positron
emission tomography; ROI, region of interest;
SDS-PAGE, sodium dodecyl sulfate polyacrylamide
gel electrophoresis; SPECT, single-photon emission
computed tomography; TATE, octreotate; US, ultrasound; USPIO, ultrasmall superparamagnetic iron
oxide; VEGF, vascular endothelial growth factor.

Competing Interests
The authors have declared that no competing
interest exists.

References
1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.
12.

Abbreviations

13.

BBB, blood-brain barrier; CDR, complementarity
determining region; CT, computed tomography;
DOTA,
1,4,7,10-tetraazacyclododecane-1,4,7,10tetraacetic acid; ELISA, Enzyme-linked immuno-

14.

15.

Grosu AL, Weber WA, Franz M et al. Reirradiation of recurrent
high-grade gliomas using amino acid PET (SPECT)/CT/MRI image
fusion to determine gross tumor volume for stereotactic fractionated
radiotherapy. International journal of radiation oncology, biology,
physics 2005; 63: 511-519.
Hofmann M, Steinke F, Scheel V et al. MRI-Based Attenuation Correction
for PET/MRI: A Novel Approach Combining Pattern Recognition and
Atlas Registration. Journal of Nuclear Medicine 2008; 49: 1875-1883.
Wintermark M, Meuli R, Browaeys P et al. Comparison of CT perfusion
and angiography and MRI in selecting stroke patients for acute
treatment. Neurology 2007; 68: 694-697.
Visser BC, Yeh BM, Qayyum A et al. Characterization of Cystic
Pancreatic Masses: Relative Accuracy of CT and MRI. American Journal
of Roentgenology 2007; 189: 648-656.
Pien HH, Fischman AJ, Thrall JH, Sorensen AG. Using imaging
biomarkers to accelerate drug development and clinical trials. Drug
Discovery Today 2005; 10: 259-266.
Zerizer I, Tan K, Khan S et al. Role of FDG-PET and PET/CT in the
diagnosis and management of vasculitis. European Journal of Radiology
2010; 73: 504-509.
Rai P, Mallidi S, Zheng X et al. Development and applications of
photo-triggered theranostic agents. Advanced Drug Delivery Reviews
2010; 62: 1094-1124.
An G, Wu F, Morris ME. 5,7-Dimethoxyflavone and multiple flavonoids
in combination alter the ABCG2-mediated tissue distribution of
mitoxantrone in mice. Pharm Res 2011; 28: 1090-1099.
Wu F, Zhang Z, Ding H. Simple high-performance liquid
chromatographic method for the determination of tetramethylpyrazine
phosphate in very small volumes of dog plasma: application to a
pharmacokinetic study. J Chromatogr Sci 2006; 44: 13-17.
Masutomi T, Onishi H, Takahashi Y, Machida Y. Biodistribution study
using Egg Protein ELISA kit after administration of FITC-labeled
ovalbumin solution and its double liposomes in the in situ loop method,
and its implication in oral immunization. Curr Drug Deliv 2010; 7:
447-452.
Hong H, Goel S, Zhang Y, Cai W. Molecular Imaging with Nucleic Acid
Aptamers. Current Medicinal Chemistry 2011; 18: 4195-4205.
Pickhardt P, Park S, Hahn L et al. Specificity of unenhanced CT for
non-invasive diagnosis of hepatic steatosis: implications for the
investigation of the natural history of incidental steatosis. European
Radiology 2012; 22: 1075-1082.
Funkhouser J. Reinventing pharma: The theranostic revolution. Current
Drug Discovery 2002; 2: 17-19.
Li M KH, et al. Comparison of Two Ultrasmall Superparamagnetic Iron
Oxides on Cytotoxicity and MR Imaging of Tumors. Theranostics 2012;
2: 76-85.
Ray P DA. Reporter Gene Imaging in Therapy and Diagnosis.
Theranostics 2012; 2: 333-334.

http://www.thno.org

Theranostics 2012, 2(11)
16. Palm S, Enmon RM, Matei C et al. Pharmacokinetics and Biodistribution
of 86Y-Trastuzumab for 90Y Dosimetry in an Ovarian Carcinoma Model:
Correlative MicroPET and MRI. Journal of Nuclear Medicine 2003; 44:
1148-1155.
17. Wen S, Liu D-F, Liu Z et al. OxLDL-targeted iron oxide nanoparticles for
in vivo MRI detection of perivascular carotid collar induced
atherosclerotic lesions in ApoE-deficient mice. Journal of Lipid Research
2012; 53: 829-838.
18. Vyjayanti VN, Rao KS. DNA double strand break repair in brain:
Reduced NHEJ activity in aging rat neurons. Neuroscience Letters 2006;
393: 18-22.
19. Reddy S, Robinson MK. Immuno-positron emission tomography in
cancer models. Semin Nucl Med 2010; 40: 182-189.
20. Voss SD, Smith SV, DiBartolo N et al. Positron emission tomography
(PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr
immunoconjugates. Proc Natl Acad Sci U S A 2007; 104: 17489-17493.
21. Dearling JL, Voss SD, Dunning P et al. Imaging cancer using PET--the
effect of the bifunctional chelator on the biodistribution of a
(64)Cu-labeled antibody. Nucl Med Biol 2011; 38: 29-38.
22. Lancelot S, Zimmer L. Small-animal positron emission tomography as a
tool for neuropharmacology. Trends Pharmacol Sci 2010; 31: 411-417.
23. Bading JR, Horling M, Williams LE et al. Quantitative serial imaging of
an 124I anti-CEA monoclonal antibody in tumor-bearing mice. Cancer
Biother Radiopharm 2008; 23: 399-409.
24. Herbertson RA, Tebbutt NC, Lee FT et al. Phase I biodistribution and
pharmacokinetic study of Lewis Y-targeting immunoconjugate
CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res
2009; 15: 6709-6715.
25. Beer AJ, H K, H-J W, Schwaiger M. PET Imaging of Integrin αVβ3
Expression. Theranostics 2011; 1: 48-57.
26. Jacobson OJ, Weiss ID, Szajek LP et al. PET imaging of CXCR4 using
copper-64 labeled peptide antagonist. Theranostics 2011; 1: 251-262.
27. Liu S LH, et al. PET Imaging of Integrin Positive Tumors Using 18F
Labeled Knottin Peptides. Theranostics 2011; 1: 403-412.
28. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody
pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;
84: 548-558.
29. Nagengast WB, de Vries EG, Hospers GA et al. In vivo VEGF imaging
with radiolabeled bevacizumab in a human ovarian tumor xenograft. J
Nucl Med 2007; 48: 1313-1319.
30. Paudyal B, Paudyal P, Oriuchi N et al. Positron emission tomography
imaging and biodistribution of vascular endothelial growth factor with
64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci
2011; 102: 117-121.
31. Hong H, Zhang Y, Engle JW et al. In vivo targeting and positron
emission tomography imaging of tumor vasculature with 66Ga-labeled
nano-graphene. Biomaterials 2012; 33: 4147-4156.
32. Petersen AL, Binderup T, Jølck RI et al. Positron emission tomography
evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a
human neuroendocrine carcinoma mouse model. Journal of Controlled
Release 2012.
33. Pimlott SL, Sutherland A. Molecular tracers for the PET and SPECT
imaging of disease. Chemical Society Reviews 2011; 40: 149-162.
34. Schneider DW, Heitner T, Alicke B et al. In vivo biodistribution, PET
imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1,
engineered antibody fragments in LNCaP tumor-bearing nude mice. J
Nucl Med 2009; 50: 435-443.
35. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing
fundamental biological processes in a new light. Genes & Development
2003; 17: 545-580.
36. Gambhir SS. Molecular imaging of cancer with positron emission
tomography. Nat Rev Cancer 2002; 2: 683-693.
37. Helbok A, Decristoforo C, Dobrozemsky G et al. Radiolabeling of
lipid-based nanoparticles for diagnostics and therapeutic applications: a
comparison using different radiometals. Journal of Liposome Research
2010; 20: 219-227.
38. DeNardo SJ, DeNardo GL, Miers LA et al. Development of Tumor
Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody
Nanoparticles) for Alternating Magnetic Field Cancer Therapy. Clinical
Cancer Research 2005; 11: 7087s-7092s.
39. Natarajan A, Gruettner C, Ivkov R et al. NanoFerrite Particle Based
Radioimmunonanoparticles:
Binding
Affinity
and
In
Vivo
Pharmacokinetics. Bioconjugate Chemistry 2008; 19: 1211-1218.
40. Misri R, Saatchi K, Ng SSW et al. Evaluation of 111In labeled antibodies
for SPECT imaging of mesothelin expressing tumors. Nuclear Medicine
and Biology 2011; 38: 885-896.

1052
41. Fang Wu, Hong Ding, Zhang Z. Investigation of the in vivo
desintegration and transit behavior of Tetramethylpyrazine phosphate
pulsincap capsule in the gastrointestinal tract of dogs by gamma
scintigraphy. Journal of Biomedical Engineering 2006; 23: 790-794.
42. Tran L, Huitema AD, van Rijswijk MH et al. CD20 antigen imaging with
124 I-rituximab PET/CT in patients with rheumatoid arthritis. Hum
Antibodies 2011; 20: 29-35.
43. Bouchelouche K, Tagawa ST, Goldsmith SJ et al. PET/CT Imaging and
Radioimmunotherapy of Prostate Cancer. Semin Nucl Med 2011; 41:
29-44.
44. Suga K, Yasuhiko K, Hiyama A et al. F-18 FDG PET/CT findings in a
patient with bilateral orbital and gastric mucosa-associated lymphoid
tissue lymphomas. Clin Nucl Med 2009; 34: 589-593.
45. Bouchelouche
K,
Capala
J,
Oehr
P.
Positron
emission
tomography/computed tomography and radioimmunotherapy of
prostate cancer. Curr Opin Oncol 2009; 21: 469-474.
46. Welch MJ. Potential of labeling monoclonal antibodies for positron
emission tomography and magnetic resonance imaging. Acta Radiol
Suppl 1990; 374: 129-133.
47. Townsend DW, Carney JPJ, Yap JT, Hall NC. PET/CT Today and
Tomorrow. Journal of Nuclear Medicine 2004; 45: 4S-14S.
48. Gonzalez Trotter DE, Manjeshwar RM, Doss M et al. Quantitation of
small-animal (124)I activity distributions using a clinical PET/CT
scanner. J Nucl Med 2004; 45: 1237-1244.
49. Heiss WD. The potential of PET/MR for brain imaging. Eur J Nucl Med
Mol Imaging 2009; 36 Suppl 1: S105-112.
50. Sharma R, Katz JK. Taxotere chemosensitivity evaluation in mice
prostate tumor: validation and diagnostic accuracy of quantitative
measurement of tumor characteristics by MRI, PET, and histology of
mice tumor. Technol Cancer Res Treat 2008; 7: 175-185.
51. Smith TA. Towards detecting the HER-2 receptor and metabolic changes
induced by HER-2-targeted therapies using medical imaging. Br J Radiol
2010; 83: 638-644.
52. Borjesson PK, Jauw YW, Boellaard R et al. Performance of
immuno-positron emission tomography with zirconium-89-labeled
chimeric monoclonal antibody U36 in the detection of lymph node
metastases in head and neck cancer patients. Clin Cancer Res 2006; 12:
2133-2140.
53. Alessio AM, Kinahan PE. Improved quantitation for PET/CT image
reconstruction with system modeling and anatomical priors. Med Phys
2006; 33: 4095-4103.
54. Minamimoto R, Ito K, Kubota K et al. Clinical Role of FDG PET/CT for
Methotrexate-Related Malignant Lymphoma. Clin Nucl Med 2011; 36:
533-537.
55. Freudenberg LS, Jentzen W, Stahl A et al. Clinical applications of
124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl
Med Mol Imaging 2011; 38 Suppl 1: S48-56.
56. Harms HJ, Knaapen P, de Haan S et al. Automatic generation of absolute
myocardial blood flow images using [15O]H2O and a clinical PET/CT
scanner. Eur J Nucl Med Mol Imaging 2011; 38: 930-939.
57. Liang H, Yang Y, Yang K et al. A microPET/CT system for in vivo small
animal imaging. Phys Med Biol 2007; 52: 3881-3894.
58. von Falck C, Rodt T, Halter R et al. Combined microPET/CT for imaging
of hepatocellular carcinoma in mice. Front Biosci 2009; 14: 2193-2202.
59. Paudyal P, Paudyal B, Iida Y et al. Dual functional molecular imaging
probe targeting CD20 with PET and optical imaging. Oncol Rep 2009; 22:
115-119.
60. Xie J, Chen K, Huang J et al. PET/NIRF/MRI triple functional iron oxide
nanoparticles. Biomaterials 2010; 31: 3016-3022.
61. Madru R, Kjellman P, Olsson F et al. 99mTc-Labeled Superparamagnetic
Iron Oxide Nanoparticles for Multimodality SPECT/MRI of Sentinel
Lymph Nodes. Journal of Nuclear Medicine 2012; 53: 459-463.
62. Weissleder R. Scaling down imaging: molecular mapping of cancer in
mice. Nat Rev Cancer 2002; 2: 11-18.
63. Hoppin J, Orcutt KD, Hesterman JY et al. Assessing antibody
pharmacokinetics in mice with in vivo imaging. J Pharmacol Exp Ther
2011; 337: 350-358.
64. Ding H, Yong K-T, Roy I et al. Gold Nanorods Coated with Multilayer
Polyelectrolyte as Contrast Agents for Multimodal Imaging. The Journal
of Physical Chemistry C 2007; 111: 12552-12557.
65. Xu Y, Chang E, Liu H et al. Proof-of-Concept Study of Monitoring
Cancer Drug Therapy with Cerenkov Luminescence Imaging. Journal of
Nuclear Medicine 2012; 53: 312-317.
66. Wu C, Mino K, Akimoto H et al. In vivo far-red luminescence imaging of
a biomarker based on BRET from Cypridina bioluminescence to an
organic dye. Proceedings of the National Academy of Sciences 2009; 106:
15599-15603.

http://www.thno.org

Theranostics 2012, 2(11)
67. Leblond F, Davis SC, Valdes PA, Pogue BW. Pre-clinical whole-body
fluorescence imaging: Review of instruments, methods and applications.
J Photochem Photobiol B 2010; 98: 77-94.
68. de Wet JR, Wood KV, DeLuca M et al. Firefly luciferase gene: structure
and expression in mammalian cells. Mol Cell Biol 1987; 7: 725-737.
69. Heim R, Cubitt AB, Tsien RY. Improved green fluorescence. Nature 1995;
373: 663-664.
70. Wu F, Tamhane M, Morris M. Pharmacokinetics, Lymph Node Uptake,
and Mechanistic PK Model of Near-Infrared Dye-Labeled Bevacizumab
After IV and SC Administration in Mice. The AAPS Journal 2012; 14:
252-261.
71. Wu F, Bhansali SG, Tamhane M et al. Noninvasive real-time fluorescence
imaging of the lymphatic uptake of BSA–IRDye 680 conjugate
administered subcutaneously in mice. Journal of Pharmaceutical
Sciences 2012; 101: 1744-1754.
72. Wu F, Bhansali S, Law W et al. Fluorescence Imaging of the Lymph Node
Uptake of Proteins in Mice after Subcutaneous Injection: Molecular
Weight Dependence. Pharmaceutical Research 2012; 29: 1843-1853.
73. Zou P, Xu S, Povoski SP et al. Near-infrared fluorescence labeled
anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal
cancer xenograft mice. Mol Pharm 2009; 6: 428-440.
74. Hulper P, Schulz-Schaeffer W, Dullin C et al. Tumor localization of an
anti-TGF-beta antibody and its effects on gliomas. Int J Oncol 2011; 38:
51-59.
75. Liang M, Liu X, Cheng D et al. Multimodality nuclear and fluorescence
tumor imaging in mice using a streptavidin nanoparticle. Bioconjug
Chem 2010; 21: 1385-1388.
76. Cohen R, Stammes M, de Roos I et al. Inert coupling of IRDye800CW to
monoclonal antibodies for clinical optical imaging of tumor targets.
EJNMMI Research 2011; 1: 31.
77. Zhang H, Yee D, Wang C. Quantum dots for cancer diagnosis and
therapy: biological and clinical perspectives. Nanomedicine (Lond) 2008;
3: 83-91.
78. Hu R, Yong KT, Roy I et al. Functionalized near-infrared quantum dots
for in vivo tumor vasculature imaging. Nanotechnology 2010; 21: 145105.
79. Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive
nonisotopic detection. Science 1998; 281: 2016-2018.
80. Yong KT, Ding H, Roy I et al. Imaging pancreatic cancer using
bioconjugated InP quantum dots. ACS Nano 2009; 3: 502-510.
81. Yong KT, Hu R, Roy I et al. Tumor targeting and imaging in live animals
with functionalized semiconductor quantum rods. ACS Appl Mater
Interfaces 2009; 1: 710-719.
82. Law WC, Yong KT, Roy I et al. Aqueous-phase synthesis of highly
luminescent CdTe/ZnTe core/shell quantum dots optimized for
targeted bioimaging. Small 2009; 5: 1302-1310.
83. Dubertret B, Skourides P, Norris DJ et al. In vivo imaging of quantum
dots encapsulated in phospholipid micelles. Science 2002; 298: 1759-1762.
84. Romero MJ, van de Lagemaat J, Mora-Sero I et al. Imaging of resonant
quenching of surface plasmons by quantum dots. Nano Lett 2006; 6:
2833-2837.
85. Michalet X, Pinaud FF, Bentolila LA et al. Quantum dots for live cells, in
vivo imaging, and diagnostics. Science 2005; 307: 538-544.
86. Hild WA, Breunig M, Goepferich A. Quantum dots - nano-sized probes
for the exploration of cellular and intracellular targeting. Eur J Pharm
Biopharm 2008; 68: 153-168.
87. Ding H, Yong KT, Law WC et al. Non-invasive tumor detection in small
animals using novel functional Pluronic nanomicelles conjugated with
anti-mesothelin antibody. Nanoscale 2011; 3: 1813-1822.
88. Ding H, Yong KT, Roy I et al. Bioconjugated PLGA-4-arm-PEG branched
polymeric nanoparticles as novel tumor targeting carriers.
Nanotechnology 2011; 22: 165101.
89. Erogbogbo F, Tien CA, Chang CW et al. Bioconjugation of luminescent
silicon quantum dots for selective uptake by cancer cells. Bioconjug
Chem 2011; 22: 1081-1088.
90. Erogbogbo F, Yong KT, Hu R et al. Biocompatible magnetofluorescent
probes:
luminescent
silicon
quantum
dots
coupled
with
superparamagnetic iron(III) oxide. ACS Nano 2010; 4: 5131-5138.
91. Erogbogbo F, Yong KT, Roy I et al. In vivo targeted cancer imaging,
sentinel lymph node mapping and multi-channel imaging with
biocompatible silicon nanocrystals. ACS Nano 2011; 5: 413-423.
92. Moriyama EH, Zheng G, Wilson BC. Optical molecular imaging: from
single cell to patient. Clin Pharmacol Ther 2008; 84: 267-271.
93. Wu F, Wuensch SA, Azadniv M et al. Galactosylated LDL nanoparticles:
a novel targeting delivery system to deliver antigen to macrophages and
enhance antigen specific T cell responses. Mol Pharm 2009; 6: 1506-1517.

1053
94. Liu L, Law WC, Yong KT et al. Multimodal imaging probes based on
Gd-DOTA conjugated quantum dot nanomicelles. Analyst 2011; 136:
1881-1886.
95. Law W, Yong K, Roy I et al. Optically and Magnetically Doped
Organically Modified Silica Nanoparticles as Efficient Magnetically
Guided Biomarkers for Two-Photon Imaging of Live Cancer Cells. J Phys
Chem C 2008; 112: 7972-7977.
96. Ding H, Wu F, Huang Y et al. Synthesis and characterization of
temperature-responsive
copolymer
of
PELGA
modified
poly(N-isopropylacrylamide). Polymer 2006; 47: 1575-1583.
97. Zhu L XJ, et al. Real-Time Video Imaging of Protease Expression In Vivo.
Theranostics 2011; 1: 18-27.
98. Ye Y, Chen X. Integrin targeting for tumor optical imaging. Theranostics
2011; 1: 102-126.
99. Qiao R, Jia Q, Hüwel S et al. Receptor-Mediated Delivery of Magnetic
Nanoparticles across the Blood–Brain Barrier. ACS Nano 2012; 6:
3304-3310.
100. Koziara JM, Lockman PR, Allen DD, Mumper RJ. &lt;i&gt;In Situ
Blood–Brain Barrier Transport of Nanoparticles. Pharmaceutical
Research 2003; 20: 1772-1778.
101. Bonoiu AC, Bergey EJ, Ding H et al. Gold nanorod–siRNA induces
efficient in vivo gene silencing in the rat hippocampus. Nanomedicine
2011; 6: 617-630.
102. Chakravarthy KV, Bonoiu AC, Davis WG et al. Gold nanorod delivery of
an ssRNA immune activator inhibits pandemic H1N1 influenza viral
replication. Proceedings of the National Academy of Sciences 2010; 107:
10172-10177.
103. Bonoiu AC, Mahajan SD, Ding H et al. Nanotechnology approach for
drug addiction therapy: Gene silencing using delivery of gold
nanorod-siRNA nanoplex in dopaminergic neurons. Proceedings of the
National Academy of Sciences 2009; 106: 5546-5550.
104. Mahajan S. D. RI, Xu GX, Yong K, Ding H., Aalinkeel R., Reynolds J. L.,
Sykes D. E., Nair B. B., Lin E. Y., Prasad P. N., Schwartz S. A.. Enhancing
the delivery of anti retroviral drug “Saquinavir” across the blood brain
barrier using nanoparticles. Current HIV Research 2010; 8: 396-404.
105. Koffie RM, Farrar CT, Saidi L-J et al. Nanoparticles enhance brain
delivery of blood–brain barrier-impermeable probes for in vivo optical
and magnetic resonance imaging. Proceedings of the National Academy
of Sciences 2011; 108: 18837-18842.
106. Banks WA. Physiology and pathology of the blood-brain barrier:
implications for microbial pathogenesis, drug delivery and
neurodegenerative disorders. Journal of Neurovirology 1999; 5: 538-555.
107. Weinstein JS, Varallyay CG, Dosa E et al. Superparamagnetic iron oxide
nanoparticles: diagnostic magnetic resonance imaging and potential
therapeutic applications in neurooncology and central nervous system
inflammatory pathologies, a review. J Cereb Blood Flow Metab 2009; 30:
15-35.
108. Atwal JK, Chen Y, Chiu C et al. A Therapeutic Antibody Targeting
BACE1 Inhibits Amyloid-β Production in Vivo. Science Translational
Medicine 2011; 3: 84ra43.
109. Yu YJ, Zhang Y, Kenrick M et al. Boosting Brain Uptake of a Therapeutic
Antibody by Reducing Its Affinity for a Transcytosis Target. Science
Translational Medicine 2011; 3: 84ra44.
110. Lee HJ, Engelhardt B, Lesley J et al. Targeting Rat Anti-Mouse
Transferrin Receptor Monoclonal Antibodies through Blood-Brain
Barrier in Mouse. Journal of Pharmacology and Experimental
Therapeutics 2000; 292: 1048-1052.
111. Boado RJ, Zhang Y, Zhang Y, Pardridge WM. Humanization of
anti-human insulin receptor antibody for drug targeting across the
human blood–brain barrier. Biotechnology and Bioengineering 2007; 96:
381-391.

http://www.thno.org

